

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

Chiara Cremolini¹, Carlotta Antoniotti¹, Alexander Stein², Johanna Bendell³, Thomas Gruenberger⁴, Daniele Rossini¹, Gianluca Masi¹, Elena Ongaro^{1,5}, Herbert Hurwitz⁶, Alfredo Falcone¹, Hans-Joachim Schmoll⁷, Massimo Di Maio⁸

Affiliations

1 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, University Hospital of Pisa, Pisa, Italy.

2 Hematology-Oncology Practice Hamburg (HOPE), University Cancer Center Hamburg, Hamburg, Germany.

3 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

4 Social Medical Center South, Department of Surgery, HPB Center Vienna Clinics and Sigmund Freud University, Medical School, Vienna, Austria.

5 Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano (PN), Italy.

6 Genentech, South San Francisco, CA.

7 Department Internal Medicine IV-Hematology-Oncology, Martin-Luther-University, Halle (Saale), Germany.

8 Department of Oncology, University of Turin, Mauriziano Hospital, Turin, Italy.

Abstract

Purpose: A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + bevacizumab is lacking because all trials that have investigated this regimen had primary end points other

than OS. To test OS with higher power and to explore the interaction of treatment effect with main patient and disease characteristics, we performed an individual patient data (IPD) meta-analysis.

Patients and Methods: IPD from 5 eligible trials were collected: CHARTA (ClinicalTrials.gov identifier: NCT01321957), OLIVIA (ClinicalTrials.gov identifier: NCT00778102), STEAM (ClinicalTrials.gov identifier: NCT01765582), TRIBE (ClinicalTrials.gov identifier: NCT00719797), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116). The primary end point was OS. Secondary end points were progression-free survival (PFS), objective response rate (ORR), R0 resection rate, grade 3/4 adverse events, and subgroup analyses according to clinical and molecular characteristics.

Results: A total of 1,697 patients were randomly assigned to FOLFOXIRI + bevacizumab (n = 846) or doublets + bevacizumab (n = 851). Most (78%) had an Eastern Cooperative Oncology Group performance status of 0, and the median age was 61 years. After a median follow-up of 39.9 months, patients assigned to FOLFOXIRI + bevacizumab had significantly longer OS than those assigned to doublets + bevacizumab (median, 28.9 v 24.5 months; hazard ratio [HR], 0.81; 95% CI, 0.72 to 0.91; $P < .001$), with no significant heterogeneity among trials ($P = .39$; $I^2 = 2\%$). No significant interaction effect between treatment arm and investigated characteristics was demonstrated. Patients assigned to FOLFOXIRI + bevacizumab had longer PFS (median, 12.2 v 9.9 months; HR, 0.74; 95% CI, 0.67 to 0.82; $P < .001$), higher ORR (64.5% v 53.6%; $P < .001$), higher R0 resection rate (16.4% v 11.8%; $P = .007$), and higher rates of grade 3/4 neutropenia (45.8% v 21.5%; $P < .001$), febrile neutropenia (6.3% v 3.7%; $P = .019$), and diarrhea (17.8% v 8.4%; $P < .001$).

Conclusion: FOLFOXIRI + bevacizumab significantly and meaningfully improves survival of patients with metastatic colorectal cancer compared with doublets + bevacizumab and provides advantage in PFS, ORR, and R0 resection rate at the price of a moderate increase in toxicity. No increased benefit is observed among patients with BRAF-mutant tumors.

Introduction

In the past 10 years, the choice of first-line therapy for patients with metastatic colorectal cancer (mCRC) has been made more complex by the increased availability of different treatment options. The anti-angiogenic bevacizumab and the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab (only for patients with RAS wild-type tumors) entered the therapeutic scenario, and different intensities of the first-line chemotherapy backbone were investigated, spanning from 1 to 3 active cytotoxics.

A phase III randomized trial by Gruppo Oncologico del Nord Ovest demonstrated the superiority of an intensified regimen, the triplet FOLFOXIRI (irinotecan 165 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², and fluorouracil 3,200 mg/m² 48-hour continuous infusion) over an irinotecan-based doublet as

upfront therapy of patients with mCRC.⁵ The trial was conducted when the role of targeted agents in this setting had not yet been well established.

More recently, several phase II and III randomized trials compared the triplet FOLFOXIRI with chemotherapy doublets (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX] or fluorouracil, leucovorin, and irinotecan [FOLFIRI]), both in combination with bevacizumab, demonstrating that the intensification of the upfront chemotherapy was beneficial for patients with mCRC at the price of an increase incidence of some hematologic and GI adverse events.⁶⁻¹² Based on these results, FOLFOXIRI + bevacizumab is included among first-line options in most clinical guidelines and recommendations worldwide.¹⁻³ However, questions are still open about the proper placement of this therapeutic choice in daily practice.

First, to fully appreciate the cost/benefit balance of this option, an accurate estimation of the magnitude of the survival benefit provided by the intensification of the upfront chemotherapy is required to evaluate the acceptability of the additional toxicity. Such estimation is currently lacking because all those trials had primary end points other than overall survival (OS), and most of them were underpowered to detect a potentially relevant survival effect. Second, the identification of clinical and/or molecular characteristics associated with a higher benefit from the triplet would be helpful in properly selecting candidate patients. To this regard, FOLFOXIRI + bevacizumab is now often used in patients with BRAF V600E-mutated mCRC based on the post hoc subgroup analysis of the TRIBE study, but results of subgroup analyses from other trials are not consistent.^{1,3,7,9,12} Based on these considerations, we conducted a systematic review followed by an individual patient data (IPD)–based meta-analysis aimed at providing a robust estimation of the added value of FOLFOXIRI + bevacizumab over conventional doublets + bevacizumab in terms of OS and at exploring the interaction of treatment effect with main patient and disease characteristics at baseline.

Patients and Methods

Identification of Studies and Collection of Data

This systematic review and meta-analysis of IPD is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.¹³ The literature search was performed in January 2019 to identify all randomized clinical trials that compared doublet (ie, FOLFIRI, irinotecan and capecitabine [XELIRI], FOLFOX, capecitabine and oxaliplatin [XELOX]) versus the triplet FOLFOXIRI, both in combination with bevacizumab, as first-line treatment of patients with mCRC. The search was carried out using PubMed, Embase, Medline, Cochrane Library, ASCO proceedings, and European Society of Medical Oncology (ESMO) proceedings, without any date restrictions. The following keywords were entered in all the possible combinations: metastatic colorectal cancer, first-line, doublet, FOLFOX, FOLFIRI, XELOX, XELIRI, triplet, FOLFOXIRI, bevacizumab, and randomized controlled trial. References of the identified articles were

checked, and principal investigators were asked whether they were aware of other published or unpublished trials. The following IPD at baseline were collected: age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, primary tumor sidedness, time to diagnosis of metastatic disease (synchronous v metachronous), previous adjuvant chemotherapy (yes v no) and type of adjuvant therapy (oxaliplatin v not oxaliplatin based), surgery on primary tumor, type of metastatic spread (involved organs at baseline), RAS and BRAF molecular status determined on tissue samples from either primary tumor or related metastases according to procedures of each study, and treatment arm (doublets + bevacizumab v FOLFOXIRI + bevacizumab). RECIST, secondary resection of metastases (yes v no) and outcome resection (R0 v R1 v R2 v palliative resection), first-line progression-free survival (PFS), and OS were also collected.

Study Quality

Each study was assessed for quality and potential bias using a structured checklist that was based on Method for Evaluating Research and Guideline Evidence (MERGE) criteria.¹⁴ Quality of randomization, blinding, outcome measures, measure assessment, arm comparability, loss to follow-up, and intention-to-treat analysis were evaluated. An overall quality score was assigned to each study, as follows: A (low risk of bias), B1 (low to moderate risk of bias), B2 (moderate to high risk of bias), or C (high risk of bias).

Data were carefully checked and verified for consistency with original publications or abstracts; discrepancies were discussed and resolved with the authors before setting up the final pooled database. The approval of a formal protocol for the IPD meta-analysis was obtained from the principal investigators of all trials.

Statistical Analysis

All the efficacy analyses were done on an intention-to-treat basis. Safety was assessed in patients who received at least 1 dose of study treatment. All the analyses were stratified by trial. All tests were two-sided.

The primary end point was OS, defined as the time since study random assignment to death as a result of any cause. Secondary end points were PFS, defined as the time since study random assignment to the first evidence of disease progression or death as a result of any cause; objective response rate (ORR), defined as the percentage of patients who experienced partial or complete response according to the version of RECIST adopted in each trial; rate of R0 surgery of metastases (ie, resection with no macroscopic or microscopic residual tumor), defined as the percentage of patients of the total number of included patients who underwent an R0 resection of metastases; and rate of treatment-related grade 3 or 4 adverse events, defined as the percentage of patients experiencing grade 3 or 4 all-cause adverse events of the total number of patients eligible for toxicity analysis. Prespecified subgroup analyses of OS and PFS were

performed to explore the consistency of the treatment effect on the outcome according to key patient and disease characteristics.

The median duration of follow-up and its interquartile range (IQR) were calculated according to the reverse Kaplan-Meier method. Distributions of time-to-event variables for OS and PFS were estimated with the use of the Kaplan-Meier product limit method. The log-rank test stratified by trial was used as primary analysis for comparisons between treatment groups. The heterogeneity among studies was quantified through the Higgins I² index. Subgroup analyses were performed by means of an interaction test. The ORR, the proportion of patients undergoing an R0 resection of metastases, and the toxicities were compared using the Mantel-Haenszel χ^2 test stratified by trial for combining 2 × 2 tables.

All statistical analyses on IPD were performed with SPSS version 25.0 for Windows (IBM Corporation, Chicago, IL). Trial-level meta-analysis to obtain plots for each trial and calculate the heterogeneity among studies was performed using the RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).

Results

Of the 101 entries returned by our search strategy, 5 eligible trials were identified: TRIBE (ClinicalTrials.gov identifier: NCT00719797), OLIVIA (ClinicalTrials.gov identifier: NCT00778102), CHARTA (ClinicalTrials.gov identifier: NCT01321957), STEAM (ClinicalTrials.gov identifier: NCT01765582), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116).^{6-10,12} One trial (METHEP-2; ClinicalTrials.gov identifier: NCT01442935) was excluded because a triple regimen other than FOLFOXIRI (ie, fluorouracil, leucovorin, irinotecan, and oxaliplatin) was used.¹⁵ Main characteristics of each study are listed in Table 1, and their detailed eligibility criteria and results have been previously reported.

In all studies, most of the evaluation criteria for the MERGE checklist were fulfilled, with overall quality score B1 (all included studies were of sufficiently high quality to consider the risk of bias as low to moderate). Overall, 1,705 (95%) of the 1,797 patients initially randomly assigned were eligible for the meta-analysis (92 patients were excluded because they had received an alternating treatment with doublets, named sequential FOLFOXIRI, in the STEAM trial). IPD were available for 1,697 patients (99.5%) who were included in the meta-analysis (8 patients randomly assigned in the CHARTA study had no available data and were excluded from the intention-to-treat population of the trial). Inclusion criteria were not the same among the 5 trials. The OLIVIA trial randomly assigned only patients with disease confined to the liver; the TRIBE2 trial included only patients who had not received an oxaliplatin-containing adjuvant therapy (Table 1). In all eligible studies, an induction phase was planned, with a duration ranging from 4 to 6 months followed by maintenance with a fluoropyrimidine (fluorouracil and leucovorin or capecitabine) +

bevacizumab until disease progression, patient refusal, unacceptable adverse events, or consent withdrawal (Table 1).

Of the 1,697 included patients, 851 (50.1%) were assigned to the doublets + bevacizumab group and 846 (49.9%) to the FOLFOXIRI + bevacizumab group. Patient demographic, clinical, and molecular characteristics are listed in Table 2. Among patients allocated in the doublets + bevacizumab group, 595 (69.9%) received treatment with FOLFOX + bevacizumab and 256 (30.1%) with FOLFIRI + bevacizumab. The median age of the pooled population was 61 years (IQR, 53-67 years); most patients had an ECOG performance status of 0 (78.3%) and presented with synchronous metastases (84.7%). Of the patients, 34.8% had a right-sided primary tumor, and 32.7% had liver-limited disease. Of 1,316 patients with available data, RAS and BRAF mutations were reported in 65% and 9%, respectively. No relevant differences between the 2 treatment groups were evident, except for a higher percentage of patients with a right-sided primary tumor (37.3% v 32.3%) and liver-only disease (35.6 v 29.9%) in the FOLFOXIRI + bevacizumab group (Table 2).

After a median follow-up of 39.9 months (IQR, 30.1-49.9 months)—40.8 months in the doublet + bevacizumab group and 38.9 months in the FOLFOXIRI + bevacizumab group—1,118 (66%) of 1,697 patients died (591 [69%] in the doublets + bevacizumab group and 527 [62%] in the FOLFOXIRI + bevacizumab group). Median OS was 28.9 months (95% CI, 27.3 to 30.4 months) in the FOLFOXIRI + bevacizumab group and 24.5 months (95% CI, 23.0 to 25.9 months) in the doublets + bevacizumab group (hazard ratio [HR], 0.81; 95% CI, 0.72 to 0.91; $P < .001$; Fig 1A). The estimated 5-year OS rate was 22.3% (95% CI, 18.0% to 26.6%) in the FOLFOXIRI + bevacizumab group and 10.7% (95% CI, 6.6% to 14.8%) in the doublets + bevacizumab group ($P < .001$). No significant heterogeneity among the 5 trials ($P = .39$; $I^2 = 2\%$; Fig 1B) was detected. Treatment effect was consistent across analyzed subgroups (Fig 2). Although in the absence of a significant P for interaction ($P = .104$), patients previously exposed to an oxaliplatin-based adjuvant therapy derived no benefit from FOLFOXIRI + bevacizumab versus doublets + bevacizumab (Data Supplement). OS results in the BRAF-mutant subgroup and according to the comparator arm (oxaliplatin v irinotecan based) are described in the Data Supplement.

A total of 1,489 (88%) patients experienced first-line disease progression (761 [89%] in the doublets + bevacizumab group and 728 [86%] in the FOLFOXIRI + bevacizumab group). Median PFS was 12.2 months (95% CI, 11.6 to 12.8 months) in the FOLFOXIRI + bevacizumab group and 9.9 months (95% CI, 9.5 to 10.3 months) in the doublets + bevacizumab group (HR, 0.74; 95% CI, 0.67 to 0.82; $P < .001$; Fig 3A). No significant heterogeneity among the 5 trials was observed ($P = .19$; $I^2 = 35\%$; Fig 3B). Treatment effect was consistent across analyzed subgroups (Data Supplement). A borderline significant interaction ($P = .058$) was found between treatment effect and the previous exposure to an oxaliplatin-based adjuvant therapy (Data Supplement).

Among 1,695 (99.9%) of the 1,697 patients evaluable for RECIST, 545 (64.5%) of 845 in the FOLFOXIRI + bevacizumab group and 456 (53.6%) of 850 in the doublets + bevacizumab group achieved an objective response (odds ratio [OR], 1.57; 95% CI, 1.29 to 1.91; $P < .001$). There was no evidence of heterogeneity among the 5 trials ($P = 1.00$; $I^2 = 0\%$; Data Supplement) or among investigated subgroups (Data Supplement).

Secondary surgery for metastases was performed with a radical curative intent (ie, R0 resection) for 139 patients (16.4%) in the FOLFOXIRI + bevacizumab group and 100 patients (11.8%) in the doublets + bevacizumab group (OR, 1.48; 95% CI, 1.12 to 1.95; $P = .007$; Data Supplement). No evidence of heterogeneity among the 5 trials was observed ($P = .33$; $I^2 = 13\%$).

A sensitivity analysis explored the survival difference between treatment arms in patients who underwent R0 resection or not following the upfront therapy. There was no significant interaction between treatment arm and the achievement of R0 resection in terms of OS ($P = .667$). In patients with R0 resection, median OS was 64.0 months with FOLFOXIRI + bevacizumab and 52.6 months with doublets + bevacizumab (HR, 0.79; 95% CI, 0.50 to 1.24), while in other patients, median OS was 25.7 and 22.3 months, respectively (HR, 0.84; 95% CI, 0.74 to 0.95; Data Supplement).

Of the 1,697 patients, 1,674 (98.6%) were included in the safety analysis (23 patients did not receive any dose of the assigned treatment and were excluded [15 in the doublets + bevacizumab arm and 8 in the FOLFOXIRI + bevacizumab arm]). Compared with doublets + bevacizumab, the administration of FOLFOXIRI + bevacizumab was associated with a significantly higher incidence of the following grade 3 or 4 adverse events: neutropenia (45.8% v 21.5%; $P < .001$), febrile neutropenia (6.3% v 3.7%; $P = .019$), nausea (5.5% v 3.0%; $P = .016$), mucositis (5.1% v 2.9%; $P = .024$), and diarrhea (17.8% v 8.4%; $P < .001$). No significant increase in the rate of toxic deaths was reported (2.3% v 1.4%; $P = .277$; Fig 4).

Discussion

The present meta-analysis of IPD from 5 randomized trials provides robust confirmation of the survival benefit from FOLFOXIRI + bevacizumab compared with doublets + bevacizumab as initial therapy of unresectable mCRC. The advantage with FOLFOXIRI + bevacizumab is not only statistically significant but also clinically meaningful: A reduction in the risk of death of 19% is reported, with a 4.4-month absolute difference in median OS and, notably, an 11.6% relative increase in the estimated 5-year OS rate that reaches 22.3% with FOLFOXIRI + bevacizumab. The consistent benefit observed in terms of PFS, ORR, and radical resections corroborates OS results. Therefore, our findings provide a reliable answer to one of the most frequently reported concerns with regard to the upfront use of the 3 cytotoxics: the short-term effect of the intensified regimen not followed by a coherent long-term benefit. The current results should be reassuring about the worry that the exposure to the 3 drugs may impair the efficacy of subsequent

therapies, thus not translating into a relevant survival advantage. Results of another randomized study that compared FOLFOXIRI + bevacizumab and FOLFOX + bevacizumab as upfront treatment of poor-prognosis mCRC with at least 3 circulating tumor cells detected at baseline were recently presented and are consistent with findings from our meta-analysis.¹¹

With the aim of improving the estimation of the cost/benefit balance of the upfront use of FOLFOXIRI + bevacizumab, the price of the intensified chemotherapy in terms of toxicity cannot be neglected. Higher incidence of grade 3 and 4 GI (diarrhea, mucositis, nausea) and hematologic (neutropenia, febrile neutropenia) adverse events was confirmed, with no increase in bevacizumab-related toxicities or fatal events. The overall incidence of febrile neutropenia was 6%, thus below the threshold for recommending the routine use of granulocyte colony-stimulating factor as primary prophylaxis.¹⁷ Of note, results are consistent among different trials conducted in different geographic areas. Quality-of-life data are missing for most of the trials, though. However, in the CHARTA study, no impairment of quality of life as assessed by means of the EORTC QLQ C30 (global health score) was reported in the FOLFOXIRI + bevacizumab group.

To minimize the impact of toxicity and maximize treatment efficacy, an appropriate selection of candidate patients is mandatory. Even if the enrollment of patients with ECOG performance status 2 was allowed in the TRIBE, TRIBE2, and CHARTA studies, the 99% of patients included in the current meta-analysis had an ECOG performance status of 0 or 1, and the median age was 61 years. In the TRIBE, TRIBE2, and STEAM trials, patients age > 75 years were not eligible, and for those between 70 and 75 years of age, an ECOG performance status of 0 was required. The same criteria should be adopted in daily practice. A pooled analysis of the TRIBE and TRIBE2 studies also showed higher rates of grade 3 and 4 diarrhea and neutropenia among patients > 70 years old, thus underlining that the higher efficacy of the triplet should be carefully balanced with the higher risk of clinically relevant toxicities in this subgroup.¹⁸ In this regard, the CHARTA study defined no age limit for eligibility, but elderly and frail patients received a first cycle of therapy at a reduced dose, and then doses were adapted based on toxicity.

Identifying disease characteristics associated with higher benefit from the intensification of the upfront chemotherapy would be helpful to draw the portrait of the ideal candidate for FOLFOXIRI + bevacizumab. Nevertheless, among investigated subgroups, no characteristics associated with higher benefit from the intensified regimen were identified. However, as previously shown in the TRIBE study, patients exposed to an oxaliplatin-based adjuvant therapy seemed not to derive benefit from FOLFOXIRI + bevacizumab compared with doublets + bevacizumab.

Overall, only a minority (20%) of patients included had a left-sided RAS and BRAF wild-type tumor as a consequence of the increased use of anti-EGFR antibodies in first-line therapy in past years, so the combination of a chemotherapy doublet with an anti-EGFR remains a preferred option in these patients.¹⁻³

Studies that investigated the added value of the intensified chemotherapy in combination with anti-EGFRs are currently ongoing: ClinicalTrials.gov identifiers: NCT03493048 and NCT01802645.^{19,20}

In past years, the use of FOLFOXIRI + bevacizumab has been often considered the preferable option in BRAF V600E–mutated tumors with the aim of rapidly counteracting the biologic aggressiveness of these poor-prognosis tumors.^{1,3} This recommendation was based on the subgroup analysis of the phase III TRIBE study showing a higher magnitude of benefit from FOLFOXIRI + bevacizumab compared with FOLFIRI + bevacizumab in the BRAF-mutated subgroup, although in the absence of a significant interaction effect between treatment arm and RAS or BRAF mutational status.⁷ These results corroborated previous findings from a prospective phase II study of FOLFOXIRI + bevacizumab in patients with BRAF V600E–mutated mCRC, which provided encouraging signals of activity.²¹ However, results of the TRIBE2 study did not confirm the suggestion of the previous TRIBE study,¹² and the present meta-analysis further challenges the role of FOLFOXIRI + bevacizumab in BRAF-mutated tumors because no increased benefit from the intensified approach is evident in this subgroup. The different comparator arm (FOLFIRI + bevacizumab in the TRIBE study v FOLFOX + bevacizumab in all the other trials) may explain these results. However, the use of FOLFOXIRI + bevacizumab should no longer be regarded as the first choice for patients with BRAF-mutant tumors, where the use of FOLFOX + bevacizumab seems the preferable upfront option.

Another decision driver for the choice of the first-line therapy is the treatment aim: In patients with the potential for resection, an active upfront treatment allows for not missing the opportunity to convert the disease to resectability.¹⁻³ Consistently, FOLFOXIRI + bevacizumab is often considered a valuable choice when the secondary resection of metastases is a pursuable treatment objective, mainly in the case of liver-limited spread.^{22,23} However, most of patients included in the present meta-analysis were not selected based on the extent of metastatic spread and/or potential conversion to resectability. In an exploratory sensitivity analysis, no interaction effect was found between treatment arm and the achievement of R0 resections, thus confirming that the benefit from FOLFOXIRI + bevacizumab is not limited to patients who undergo radical resection of their lesions and indirectly demonstrates that the survival benefit reported with FOLFOXIRI + bevacizumab is not only due to the higher rate of patients converted to R0 resection.

In conclusion, on the basis of the results of our meta-analysis, FOLFOXIRI + bevacizumab is a valuable upfront option able to provide a clinically meaningful survival benefit to patients with unresectable mCRC with an ECOG performance status of 0 or 1. Assessment of the value of the addition of bevacizumab to FOLFOXIRI or the comparative efficacy versus doublets plus anti-EGFR in patients with RAS wild-type tumors is out of the reach of the current work. Younger patients with right-sided and/or RAS-mutated tumors not exposed to a previous oxaliplatin-based adjuvant regimen may be the best candidates for this approach independently of the conversion intent. The personalized estimation of the cost/benefit balance

of chemotherapy intensification should take into account patient-related characteristics, including personal beliefs, attitudes, and expectations.

Data Supplement

Authors retain all rights in any data supplements associated with their articles

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify approved uses, the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ASCO and JCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Readers should contact the corresponding author with any comments related to Data Supplement materials.

Authors' Disclosures of Potential Conflicts of Interest

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

References

1. Van Cutsem E, Cervantes A, Adam R, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 27:1386-1422, 2016
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology—Colon Cancer; Version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

3. Yoshino T, Arnold D, Taniguchi H, et al: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann Oncol* 29:44-70, 2018
4. Cremolini C, Schirripa M, Antoniotti C, et al: First-line chemotherapy for mCRC—a review and evidence-based algorithm. *Nat Rev Clin Oncol* 12:607-619, 2015
5. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. *J Clin Oncol* 25:1670-1676, 2007
6. Loupakis F, Cremolini C, Masi G, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 371:1609-1618, 2014
7. Cremolini C, Loupakis F, Antoniotti C, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol* 16:1306-1315, 2015
8. Gruenberger T, Bridgewater J, Chau I, et al: Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial. *Ann Oncol* 26:702-708, 2015
9. Schmoll H, Garlipp B, Junghanß C, et al: O-023FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome. *Ann Oncol* 29, 2018 (suppl; abstr O-023)
10. Hurwitz HI, Tan BR, Reeves JA, et al: Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus FOLFOX-bevacizumab for metastatic colorectal cancer (STEAM). *Oncologist* 24:921-932, 2019
11. Sastre J, Vieitez JM, Gomez-España MA, et al: Randomized phase III study comparing FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥ 3 baseline circulating tumor cells (bCTCs). *J Clin Oncol* 37, 2019 (suppl; abstr 3507)
12. Cremolini C, Antoniotti C, Rossini D, et al: Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol* 21:497-507, 2020
13. Stewart LA, Clarke M, Rovers M, et al: Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: The PRISMA-IPD statement. *JAMA* 313:1657-1665, 2015
14. Liddle J: Method for Evaluating Research and Guideline Evidence. *N S W Public Health Bull* 8:5, 1996

15. Ychou M, Rivoire M, Thezenas S, et al: Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial. *J Clin Oncol* 36, 2018 (suppl; abstr 3535)
16. Stein A, Glocksien G, Wienke A, et al: Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: Presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. *BMC Cancer* 12:356, 2012
17. Klastersky J, de Naurois J, Rolston K, et al: Management of febrile neutropenia: ESMO clinical practice guidelines. *Ann Oncol* 27:v111-v118, 2016
18. Marmorino F, Rossini D, Lonardi S, et al: Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies. *Ann Oncol* 30:1969-1977, 2019
19. Borelli B, Moretto R, Lonardi S, et al: TRIPLET: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. *ESMO Open* 3:e000403, 2018
20. Mazarin T, Ghiringhelli F, Mollevi C, et al: UCGI 28 Panirinox: A randomized phase II study assessing panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. *Ann Oncol* 29:viii204, 2018
21. Loupakis F, Cremolini C, Salvatore L, et al: FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. *Eur J Cancer* 50:57-63, 2014
22. Cremolini C, Casagrande M, Loupakis F, et al: Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. *Eur J Cancer* 73:74-84, 2017
23. Tomasello G, Petrelli F, Ghidini M, et al: FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: A systematic review and pooled analysis. *JAMA Oncol* 3:e170278, 2017

TABLE 1
Characteristics of the five randomized trials included in the meta-analysis

Characteristic	TRIBE	OLIVIA	CHARTA	STEAM	TRIBE2
Phase of the study	III	II	II	II	III
Country	Italy	Austria, France, Spain, and United Kingdom	Germany	United States	Italy
Treatment of control arm	FOLFIRI + Bev	FOLFOX + Bev	FOLFOX + Bev	FOLFOX + Bev	FOLFOX + Bev
Primary end point	PFS	Overall resection rate	PFR at 9 months	ORR and PFS	PFS2
Planned No. of participants	(n = 450)	(n = 80)	(n = 250)	(n = 280) ^a	(n = 654)
Actual No. of participants	(N = 508)	(N = 80)	(N = 242)	(N = 280) ^a	(N = 679)
Start of the accrual	July 2008	October 2008	July 2011	January 2013	February 2015
End of the accrual	May 2011	December 2011	December 2014	December 2014	May 2017
No. of participating sites	34	16	51	45	58
Median follow-up, months	48.1	28.3	57.1	22.2	35.9
Trial quality (MERGE criteria)	B1	B1	B1	B1	B1
Eligibility criteria					
Age, years	18-75	≥ 18	≥ 18	18-75	18-75
ECOG performance status	0-2 ^b	0-1	0-2	0-1 ^c	0-2 ^b
Previous oxaliplatin-based adjuvant therapy	Allowed	Allowed	Allowed	Allowed	Not allowed
Time between end of adjuvant therapy and relapse, months	> 12	> 6	> 6	> 12	> 6
Type of metastatic spread	Any site	Liver only	Any site	Any site	Any site
Planned treatment					
Duration of induction	Up to 6 months/12 cycles	Up to 6 months/12 cycles	Up to 6 months/12 cycles	Up to 4-6 months/8-12 cycles	Up to 4 months/8 cycles
Schedule of maintenance	FU and Bev	FU and Bev	FU or cape + Bev	FU or Cape + Bev	FU and Bev
RECIST version	1.0	1.0	1.1	1.1	1.1

Abbreviations: FU, fluorouracil in combination with leucovorin; Bev, bevacizumab; Cape, capecitabine; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, infusional fluorouracil, leucovorin, and irinotecan; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; MERGE, Method for Evaluating Research and Guideline Evidence; ORR, overall response rate; PFR, progression-free rate; PFS, progression-free survival; PFS2, progression-free survival 2.

^aConsidering 3 arms of treatment from the original trial design.

^bECOG performance status 0-2 if age ≤ 70 years or 0 if age 71-75 years.

^cECOG performance status 0-1 if age ≤ 70 years or 0 if age 71-75 years.

TABLE 2

Baseline patient and tumor characteristics of the pooled population (N = 1,697)

Characteristic	Group, No. (%)	
	Control (n = 851)	Experimental (n = 846)
Median age, years (IQR)	61 (53-67)	60 (53-67)
Sex		
Male	518 (61)	489 (58)
Female	333 (39)	357 (42)
ECOG performance status		
0	656 (77)	667 (79)
1	180 (21)	168 (20)
2	12 (2)	7 (1)
Missing	3	4
Time to metastasis		
Synchronous	720 (85)	716 (85)
Metachronous	130 (15)	130 (15)
Missing	1	0
Prior adjuvant chemotherapy		
No	790 (93)	782 (92)
Yes	61 (7)	63 (8)
Missing	0	1
Primary tumor site		
Right	255 (32)	295 (37)
Left	418 (53)	389 (49)
Rectum	117 (15)	107 (14)
Missing	61	55
Liver-only disease		
Yes	254 (30)	300 (36)
No	596 (70)	543 (64)
Missing data	1	3
Surgery on primary tumor		
Yes	465 (55)	445 (53)
No	386 (45)	400 (47)
Missing	0	1
<i>RAS</i> and <i>BRAF</i> status		
<i>RAS</i> and <i>BRAF</i> wild type	172 (26)	177 (27)
<i>RAS</i> mutated	430 (66)	422 (64)
<i>BRAF</i> mutated	54 (8)	61 (9)
Missing	195	186
Primary tumor site and <i>RAS</i> and <i>BRAF</i> status		
Right and <i>RAS</i> and <i>BRAF</i> wild type	31 (5)	44 (7)
Right and <i>RAS</i> mutated	149 (23)	168 (26)
Right and <i>BRAF</i> mutated	40 (6)	39 (6)
Left and <i>RAS</i> and <i>BRAF</i> wild type	134 (21)	132 (20)
Left and <i>RAS</i> mutated	273 (43)	250 (38)
Left and <i>BRAF</i> mutated	13 (2)	22 (3)
Missing	211	191

Abbreviations: ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range.

Fig 1. (A) Overall survival (OS) curves by treatment arm. (B) Forest plot of treatment effect on OS. Bev, bevacizumab; FOLFOXIRI, infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan; HR, hazard ratio; IV, inverse variance.




Fig 2. Treatment effect on overall survival within main clinical and molecular subgroups. Bev, bevacizumab; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOXIRI, infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan; HR, hazard ratio; mut, mutation; wt, wild type.




Fig 3. (A) Progression-free survival (PFS) curves by treatment arm. (B) Forest plot of treatment effect on PFS. Bev, bevacizumab; FOLFOXIRI, infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan; HR, hazard ratio; IV, inverse variance.






Fig 4. Odds ratios (ORs) of most frequent grade 3 or 4 adverse events. (*) Excludes patients in the TRIBE study. Bev, bevacizumab; FOLFOXIRI, infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan; oxa, oxaliplatin.



Individual patient data meta-analysis of FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable metastatic colorectal cancer


Chiara Cremolini, Carlotta Antoniotti, Alexander Stein, Johanna Bendell, Thomas Gruenberger, Daniele Rossini, Gianluca Masi, Elena Ongaro, Herbert Hurwitz, Alfredo Falcone, Hans Joachim Schmoll, Massimo Di Maio

Supplementary Figure 1. Overall survival curves by treatment arm according to the previous exposure to an adjuvant oxaliplatin-based therapy or not. (N=23 patients with missing details about the type of adjuvant therapy received were excluded)




Interaction p = 0.104


Supplementary Figure 2. Overall survival curves by treatment arm in patients with *BRAF* mutant tumors




Supplementary Figure 3. Overall survival curves by treatment in patients with *BRAF* mutant tumors, according to the comparator arm




Supplementary Figure 4. Treatment effect on progression free survival within clinical and molecular subgroups




Supplementary Figure 5. Progression free survival curves by treatment arm according to the previous exposure to an adjuvant oxaliplatin-based therapy or not (N=23 patients with missing details about the type of adjuvant therapy received were excluded)




Supplementary Figure 6. Forest plot of treatment effect on objective response rate




Supplementary Figure 7. Treatment effect on objective response rate within clinical and molecular subgroups



Supplementary Figure 8. Forest plot of treatment effect on R0 resection rate




Supplementary Figure 9. Overall survival curves by treatment arm in patients achieving (A) or not (B) R0 resection of metastases.



Patients at risk

100	99	85	46	26	2	1
139	137	114	65	19	6	1



Patients at risk

751	578	292	123	29	7	3
707	567	332	125	41	9	1